A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

Inclusion Criteria Patients must have: HIV-1 seropositivity. CD4 count >= 550 cells/mm3. Asymptomatic disease. No prior antiretroviral therapy. Consent of parent or guardian if less than 18 years old. PER AMENDMENT 6/18/96: Patients with an undocumented history of oral candidiasis or a history of candidiasis that was antibiotic associated may enroll. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Medical condition that precludes study compliance. Concurrent Medication: Excluded: Antiretrovirals other than study drugs. Biologic response modifiers including erythropoietin and G-CSF. Systemic corticosteroids. Systemic cytotoxic chemotherapy. Intravenous pentamidine. Concurrent Treatment: Excluded: Systemic radiation therapy. Patients with the following prior conditions are excluded: History of grade 2 or worse peripheral neuropathy. History of pancreatitis or factors predisposing to pancreatitis. Prior Medication: Excluded: Prior antiretrovirals. Systemic immunomodulators (e.g., gp120, gp160, IL-2, interferons) within 3 months prior to study entry. Chronic alcoholism.